Vertex Pharmaceuticals

Latest Headlines

Latest Headlines

EU OKs Vertex cystic fibrosis drug Kalydeco

About 6 months after the FDA gave the nod to Vertex Pharmaceuticals' pricey drug Kalydeco, the European Commission also approved the treatment for patients with cystic fibrosis that have a certain genetic mutation.

Vertex flubbed data on Kalydeco-plus CF treatment

Vertex Pharmaceuticals had to revise data on its proposed combination therapy for cystic fibrosis after learning an initial analysis was faulty.

Astellas, Lilly grab social-media limelight

Social media buzz can be both good and bad, and smart companies want to keep track of both.

Vertex chief's pay dropped to $13.4M last year

Outgoing Vertex Pharmaceuticals CEO Matthew Emmens saw his 2011 compensation drop slightly, despite the company's successful launch of its new hepatitis C drug, Incivek.

Merck says Victrelis can interfere with HIV meds

Merck ($MRK) has notified doctors that its new hepatitis C drug Victrelis interferes with commonly used AIDS drugs. Victrelis can reduce the effectiveness of the HIV-fighters--and vice-versa--Merck...

One father's heartbreak inspired a $250M quest for a cure

How one father's loss turned into gain for cystic fibrosis patients and Vertex Pharmaceuticals ($VRTX): After the death of his son, Boston businessman Joe O'Donnell spent years raising $250 million

How do the 12 priciest drugs in the U.S. stack up?

Last week, Vertex Pharmaceuticals ($VRTX) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as

Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarter

Another day, another round of earnings calls. Today's roundup includes Allergan, which received a boost from Botox, a widely known wrinkle-fighter that is now garnering approvals around the world for

Vertex backs up pricey new CF drug with co-pay help

Vertex Pharmaceuticals ($VRTX) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's...

Interview: Vertex CEO worries about 'hyper-focus' on hep C

No question that Vertex Pharmaceuticals ($VRTX) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who